Day One Biopharmaceuticals, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Day One Biopharmaceuticals, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Day One Biopharmaceuticals, Inc. do? Business model and key facts
Get the full picture of Day One Biopharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 181
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Stocks related to Day One Biopharmaceuticals, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Day One Biopharmaceuticals, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Day One Biopharmaceuticals, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
